目的 探討復(fù)方雪蓮膠囊聯(lián)合枸櫞酸托法替布片治療類風(fēng)濕關(guān)節(jié)炎的臨床療效。方法 選取黃山首康醫(yī)院在2022年7月—2024年6月收治的類風(fēng)濕關(guān)節(jié)炎患者共68例，按隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組34例。對(duì)照組口服枸櫞酸托法替布片，1片/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服復(fù)方雪蓮膠囊，2粒/次，2次/d。兩組患者總共治療12周。比較兩組的治療效果、關(guān)節(jié)體征、疼痛程度、疾病活動(dòng)度、血清指標(biāo)。結(jié)果 與對(duì)照組的總有效率67.65%對(duì)比，治療組的總有效率88.24%更高，組間差異顯著（P＜0.05）。治療后，兩組的關(guān)節(jié)壓痛數(shù)、腫脹數(shù)、VAS評(píng)分顯著降低（P＜0.05）；治療組的關(guān)節(jié)壓痛數(shù)、腫脹數(shù)、VAS評(píng)分明顯低于對(duì)照組（P＜0.05）。治療后，兩組的DAS28-ESR評(píng)分均明顯減?。?i>P＜0.05），治療組的DAS28-ESR評(píng)分與對(duì)照組比較更小（P＜0.05）。治療后，兩組的類風(fēng)濕因子（RF）、抗環(huán)瓜氨酸肽（CCP）抗體、白細(xì)胞介素（IL）-8、IL-2R、IL-1β均明顯降低（P＜0.05）；治療組的RF、抗CCP抗體、IL-8、IL-2R、IL-1β均低于對(duì)照組（P＜0.05）。結(jié)論 復(fù)方雪蓮膠囊聯(lián)合枸櫞酸托法替布片可提高類風(fēng)濕關(guān)節(jié)炎的治療效果，減輕關(guān)節(jié)疼痛程度和體征，降低疾病活動(dòng)度，降低炎癥反應(yīng)。

Objective To explore the clinical efficacy of Compound Xuelian Capsules combined with Tofacitinib Citrate Tablets in treatment of rheumatoid arthritis. Methods A total of 68 patients with rheumatoid arthritis admitted by Huangshan Shoukang Hospital from July 2022 to June 2024 were selected and divided into control group and treatment group according to the random number table, with 34 cases in each group. The control group patients took Tofacitinib citrate tablets, twice daily, 1 tablets per time. On the basis of the control group, patients in the treatment group took Compound Xuelian Capsules, twice daily, 2 capsules/time. The treatment efficacy, joint signs, pain level, disease activity, and serum indicators between the two groups were compared. ResultsCompared with the control group, the total effective rate of the treatment group was higher, and the difference between the groups was significant (P < 0.05). The number of joint tenderness, swelling, and VAS score in both groups were significantly decreased (P < 0.05), and the number of joint tenderness, swelling, and VAS score in the treatment group were significantly lower than those in the control group (P < 0.05). The DAS28-ESR in both groups were significantly reduced (P < 0.05). Compared with the control group, the DAS28-ESR score in the treatment group were smaller (P < 0.05). The levels of RF, anti CCP antibodies, IL-8, IL-2R, and IL-1β in both groups after treatment were significantly reduced (P < 0.05). The levels of RF, anti CCP antibodies, IL-8, IL-2R, and IL-1β in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of Compound Xuelian Capsules and Tofacitinib Citrate Tablets can improve the therapeutic effect of rheumatoid arthritis, further reduce joint pain and signs, lower disease activity, and alleviate inflammatory reactions.

R977